Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Scienture Holdings, Inc. (SCNX)

Scienture Q3 preliminary revenue up 256% to $1.22 million; Nasdaq bid price issue closed

Positive Impact 4 of 5 earnings Written later

Scienture Holdings reported preliminary, unaudited revenue of about $1.22 million for the quarter ended September 30, 2026, up 256% from about $344,000 in the second quarter, driven by the August 2026 REZENOPY launch and continued Arbli sales growth. The company also regained compliance with Nasdaq's $1.00 minimum bid price requirement, and Nasdaq closed the matter, so its common stock will remain listed. The filing does not report profit or earnings per share for the quarter.

Key points

  • Preliminary unaudited Q3 2026 revenue of about $1.22 million, versus about $344,000 in Q2 2026 (up 256%).
  • Arbli wholesale unit sales rose 74% sequentially; REZENOPY launched in August 2026 with initial wholesale shipments.
  • On October 19, 2026, Nasdaq confirmed the stock closed at or above $1.00 for ten consecutive trading days, and the matter is closed.

The filing

CompanyScienture Holdings, Inc. (SCNX)
Form8-K, current report
Filed with the SECOct 19, 2026, 4:05 PM ET
Accession number0001493152-26-047579

Items reported: 2.02 Results of Operations3.01 Delisting / Listing Rule Notice

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 19, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.